I agree with F1ash, a licensing deal with substantial payment up front and then royalties would be a smart business model. Isn't that what Regeneron does? And didn't Leo mention the REGN model in a press release? (Anyone comparing stocks, beware: RGEN is Repligen, not Regeneron, which is REGN)

Also: the idea that Prurisol might not just be a one-disease treatment is a good thing to consider. Several years ago, I repeatedly (or maybe, ad nauseam) mentioned that if Prurisol worked on psoriasis, maybe it could halt psoriatic arthritis too -- and if it worked on psoriatic, which is a form of rheumatoid, maybe it would work on rheumatoid in general also.

This is ALL utter speculation until we have the Prurisol results, of course. And it very well may be that if P works, the only thing it works on is the skin lesions. We'll know pretty soon if it works for the application it's being tested for.